Despite advances in prostate cancer diagnosis and management, morbidity from prostate
cancer remains high. Approximately 20% of men present with advanced or metastatic …

Prostate cancer (PC) remains a leading cause of cancer-related deaths among men
worldwide, despite continuously improved treatment strategies. Patients with metastatic …

Dihydrotestosterone (DHT) is regarded as the most potent natural androgen and is
implicated in the development and progression of castration resistant prostate cancer …

The human adrenal produces more 19 carbon (C 19) steroids, by mass, than either
glucocorticoids or mineralocorticoids. However, the mechanisms regulating adrenal C 19 …

While androgen deprivation therapy (ADT) remains the primary treatment for metastatic
prostate cancer (PCa) since the seminal recognition of the disease as androgen-dependent …

BACKGROUND Antibody–drug conjugates (ADCs) are an emerging class of cancer
therapies that have demonstrated favorable activity both as single agents and as …

Purpose: Tumor androgens in castration-resistant prostate cancer (CRPC) reflect de novo
intratumoral synthesis or adrenal androgens. We used CB-17 SCID mice in which we …

The aldo-keto reductase 1C3 (AKR1C3) isoform plays a vital role in the biosynthesis of
androgens and is considered an attractive target in prostate cancer (PCa). No AKR1C3 …

Prostate cancer is the second leading cause of cancer death in the United States. Treatment
of localized high-risk disease and de novo metastatic disease frequently leads to relapse …

Steroid hormones play a central role in the maintenance and progression of prostate cancer.
The androgen receptor is the primary driver of tumor cell proliferation and is activated by the …